Vaccines
•48 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (48)
%
| Company | Market Cap | Price |
|---|---|---|
|
Capvaxive pneumococcal vaccine and the broader vaccine portfolio (including Gardasil) represent Merck's vaccines business.
|
$200.78B |
$79.96
-0.16%
|
|
Pfizer produces vaccines (Comirnaty, Prevnar, Abrysvo) and maintains a significant vaccines portfolio.
|
$137.19B |
$24.09
-0.15%
|
|
Sanofi develops and markets vaccines (e.g., pneumococcal PCV-21 and vaccine collaborations).
|
$120.19B |
$98.46
|
|
CVS sells vaccines through in-store pharmacies and clinics, a core health offering.
|
$98.55B |
$77.90
-0.33%
|
|
GSK's portfolio includes multiple vaccines (Arexvy, Shingrix, Penmenvy), making Vaccines a core product area.
|
$88.43B |
$21.73
|
|
Zoetis develops and commercializes vaccines for animals.
|
$62.82B |
$141.11
-1.59%
|
|
Takeda's dengue vaccine QDENGA demonstrates a clear vaccines product line with strong global demand.
|
$43.58B |
$27.33
-2.62%
|
|
QDENGA is a dengue vaccine, categorized under Vaccines.
|
$43.47B |
$13.71
-1.01%
|
|
BioNTech directly develops and commercializes vaccines, including its COVID-19 vaccine franchise and ongoing vaccine-related therapies.
|
$24.47B |
$102.06
-2.54%
|
|
Beyfortus RSV vaccine and other vaccine programs position the company in the vaccine segment.
|
$11.96B |
$14.34
+1.63%
|
|
Moderna directly develops and sells vaccines using its mRNA platform (e.g., Spikevax and pipeline vaccines like mRESVIA and mRNA-1283), which are core products highlighted in the article.
|
$10.38B |
$26.83
-3.42%
|
|
Vaccines are a key product line in Elanco's portfolio (pet and farm vaccines mentioned).
|
$9.74B |
$19.61
+3.59%
|
|
Core business is developing vaccines, including lead pneumococcal conjugate vaccines (VAX-24, VAX-31) and a platform enabling broader serotype coverage.
|
$5.64B |
$43.70
+3.75%
|
|
Vaccine vectors and tumor-associated antigen targets indicate vaccine product platform.
|
$2.40B |
$2.54
+0.20%
|
|
Direct product: vaccines for animal health as part of Phibro's Animal Health segment.
|
$1.57B |
$38.04
+0.34%
|
|
Novavax directly develops and commercializes vaccines (e.g., Nuvaxovid) and licenses its Matrix-M adjuvant/platform, making 'Vaccines' the primary investable product category.
|
$1.38B |
$8.55
+2.64%
|
|
The company is developing infectious disease vaccines, including respiratory programs licensed to GSK and non-respiratory vaccine initiatives.
|
$1.21B |
$5.38
-0.74%
|
|
ModeX's Epstein–Barr Virus (EBV) vaccine candidate constitutes a Vaccine product development program.
|
$1.20B |
$1.51
-3.21%
|
|
HEPLISAV-B is a hepatitis B vaccine and the pipeline includes multiple vaccine candidates, directly aligning with the Vaccines category.
|
$1.20B |
$9.96
-3.49%
|
|
Valneva directly develops, manufactures, and commercializes vaccines (IXIARO, DUKORAL, IXCHIQ) and has Lyme, chikungunya, Shigella, and Zika vaccine candidates in its pipeline, representing its core product category.
|
$720.26M |
$10.37
-3.62%
|
|
OCG500 vaccine-related program (IND) places Ocugen in the vaccines domain.
|
$516.90M |
$1.79
+1.41%
|
|
KOSTAIVE COVID-19 vaccine and BARDA/CSL Seqirus vaccine programs constitute direct vaccine products.
|
$513.94M |
$18.95
-5.11%
|
|
Emergent directly develops and commercializes vaccines (BioThrax, ACAM2000) as core Medical Countermeasure products.
|
$483.62M |
$8.91
+0.45%
|
|
DCVax-L and DCVax-Direct function as dendritic cell–based vaccines.
|
$358.65M |
$0.25
+2.66%
|
|
Capricor's StealthX exosome platform is being developed for vaccines, including a Project NextGen collaboration, making Vaccines a direct product/line.
|
$324.07M |
$7.09
-6.96%
|
|
Vaccinia-based viral platform used for therapy; sometimes categorized as vaccines or viral therapies.
|
$191.32M |
$5.07
-7.82%
|
|
Lead candidate is a cancer immunotherapy vaccine, directly describing a vaccine product category.
|
$169.25M |
$10.58
-5.11%
|
|
TNX-801 is a live-virus vaccine candidate for mpox and smallpox, aligning with the vaccines category.
|
$155.21M |
$21.19
-4.46%
|
|
Maintains cancer vaccine programs (breast and ovarian cancer vaccines) as key offerings.
|
$139.47M |
$4.33
-12.35%
|
|
Tevogen is developing a T cell vaccine leveraging PredicTcell technology, aligning with the Vaccines product category.
|
$131.50M |
$0.72
-3.36%
|
|
IPF/TNG platforms could be related to vaccines or vaccine-like immunotherapies, placing the company in the Vaccines category.
|
$109.82M |
$0.32
|
|
HilleVax is a vaccine-focused biotech developing norovirus vaccines (HIL-214.00 and HIL-216.00), directly aligning with the Vaccines tag.
|
$104.79M |
$2.09
|
|
The platform includes DNA medicine approaches with vaccine-like applications (e.g., Ebola booster, COVID-19 DMAbs), aligning with the Vaccines category.
|
$94.25M |
$2.57
-1.91%
|
|
Helocyte's Triplex vaccine program (immunology/vaccine modality) is part of Fortress's diversified pipeline.
|
$80.13M |
$2.71
-3.56%
|
|
Core product focus on vaccines (norovirus, COVID-19, avian influenza) using the VAAST oral vaccine platform.
|
$79.22M |
$0.35
-1.41%
|
|
First Defense provides passive immunoglobulin-based protection against calf scours, a vaccine-like immunization product for livestock.
|
$61.45M |
$6.80
+1.49%
|
|
Internal universal dengue vaccine asset represents a vaccine development program among MindWalk's assets.
|
$59.46M |
N/A
|
|
Infectious disease vaccine platform (Infectimune) and the universal flu vaccine candidate PDS0202 place the company in the vaccines category.
|
$43.30M |
$0.95
-5.27%
|
|
The company develops vaccines, specifically therapeutic cancer vaccines using its T-win platform.
|
$36.37M |
$0.55
-4.81%
|
|
Product pipeline includes recombinant vaccine antigens (e.g., Mpox ferritin antigen) and vaccine-related proteins, tying to vaccines development/production.
|
$31.60M |
$1.05
-7.08%
|
|
PMN is actively developing vaccine programs (PMN311 and PMN400), making Vaccines a direct product category for the company.
|
$16.28M |
$0.50
+4.64%
|
|
Travelan (IMM-124E) and related gut-health antibody products are prophylactic biologics targeting enteric pathogens, aligning with the Vaccines category.
|
$11.80M |
$2.07
-2.36%
|
|
GeoVax directly develops and commercializes vaccines using its MVA vector platform (e.g., GEO-MVAMpox/smallpox and GEO-CM04S1 COVID-19).
|
$8.44M |
$0.56
-7.43%
|
|
Directly develops and commercializes vaccines, including personalized cancer vaccines (EVX-01) and infectious disease vaccines under development.
|
$6.39M |
$5.90
-9.65%
|
|
ALZN002 is an active immunotherapy vaccine for Alzheimer's, aligning with Vaccines.
|
$6.31M |
$2.18
-5.63%
|
|
ThermoVax vaccine thermostabilization platform and RiVax-based vaccines position Soligenix in Vaccines.
|
$5.48M |
$1.68
-5.08%
|
|
PlaCCine includes a COVID-19 vaccine candidate (IMNN-101), placing the company in Vaccines.
|
$5.23M |
$5.37
-0.56%
|
|
Bria-IMT/Bria-OTS involve cellular therapies with vaccine-like components, aligning with Vaccines category.
|
$4.69M |
$12.40
-2.21%
|
Loading industry metrics...
Loading comparison data...
